University of California, San Diego (UC San Diego, UCSD)

University / College


Location: La Jolla, CA, United States (USA) (US) US

ISNI: 0000000121074242

ROR: https://ror.org/0168r3w48

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

A Suzaku, NuSTAR, and XMM-Newton view on variable absorption and relativistic reflection in NGC 4151 (2017) Beuchert T, Markowitz AG, Dauser T, Garcia J, Keck ML, Wilms J, Kadler M, et al. Journal article Electronic structure and ultrafast dynamics of FeAs-based superconductors by angle- and time-resolved photoemission spectroscopy (2017) Avigo I, Thirupathaiah S, Rienks EDL, Rettig L, Charnukha A, Ligges M, Cortes R, et al. Journal article Distinct Pattern of Microgliosis in the Olfactory Bulb of Neurodegenerative Proteinopathies (2017) Kohl Z, Schlachetzki J, Feldewerth J, Hornauer P, Muench M, Adame A, Riemenschneider MJ, et al. Journal article SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS (PSA) THROUGH 3 YEARS: EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL (2017) Hall S, Mease P, Kavanaugh A, Reimold A, Tahir H, Rech J, Geusens P, et al. Conference contribution Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 2-year efficacy and safety results from the phase 3 randomised, double-blind, placebo-controlled trial FUTURE 1 (2017) Rech J, Reinhardt M, Kavanaugh A, Geusens P, Mpofu S Conference contribution APREMILAST TREATMENT AND LONG-TERM (UP TO 156 WEEKS) IMPROVEMENTS IN DACTYLITIS AND ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF A LARGE DATABASE OF THE PHASE III CLINICAL DEVELOPMENT PROGRAM (2017) Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, et al. Conference contribution DURABILITY OF APREMILAST RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS: LONG-TERM (208-WEEK) RESULTS FROM THE PALACE 1 TRIAL (2017) Kavanaugh A, Gladman DD, Gomez-Reino JJ, Hall S, Lespessailles E, Mease PJ, Schett G, et al. Conference contribution Consistent Safety Profile with up to 4 Years of Apremilast Treatment: Analysis of Data from 1,493 Subjects with Psoriatic Arthritis in 3 Large, Phase III, Long-Term Studies (2017) Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, et al. Conference contribution Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study (2017) Feagan BG, Sandborn WJ, D'Haens G, Panes J, Kaser A, Ferrante M, Louis E, et al. Journal article Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic (2017) O'Bryant SE, Mielke MM, Rissman RA, Lista S, Vanderstichele H, Zetterberg H, Lewczuk P, et al. Journal article